CD52 (CAMPATH-1)

Journal of Biological Regulators and Homeostatic Agents

Volumn 15, Issue 4, 2001, Pages 386-391

  Hale, G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CD52 ANTIGEN; CELL SURFACE PROTEIN; FLUDARABINE; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOGLOBULIN M; LIGAND; SPERM ANTIBODY; SPERM ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PEPTIDE; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN STRUCTURE; ARTICLE; B CELL LEUKEMIA; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ACTIVATION; CELLULAR DISTRIBUTION; CHROMOSOME 1; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOG; DRUG MECHANISM; DRUG STRUCTURE; GENE TARGETING; HUMAN; HUMAN CELL; KNOCKOUT GENE; LIGAND BINDING; MALE; MONKEY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; RAT; SIDE EFFECT; SIGNAL TRANSDUCTION; SPECIES COMPARISON; STEM CELL TRANSPLANTATION; TISSUE DISTRIBUTION; ALLELE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; NEOPLASM; PHYSIOLOGY; REVIEW; SEQUENCE HOMOLOGY;

ANIMALIA; CANIS FAMILIARIS;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; GLYCOPROTEINS; HUMANS; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; PHENOTYPE; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 0035544728     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Structure of the CAMPATH-1 antigen, a GPI-anchored glycoprotein which is an exceptionally good target for complement lysis
2. Primary structure of CD52
3. Recognition of CD52 allelic gene products by CAMPATH-1H antibodies
4. Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor
5. Identification and gene cloning of a new phosphatidylinositol-linked antigen expressed on mature lymphocytes. Down-regulation by lymphocyte activation
6. CD52 is the "major maturation-associated" Sperm membrane antigen
7. Gene expression in the dog epidydymis: A model for human epidydymal function
8. Purification and preliminary characterization of the CAMPATH-1 antigen
9. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein
10. CD52 Workshop Panel Report
11. Sperm immobilizing and fertilization-blocking monoclonal antibody 2C6 to human seminal plasma antigen and characterization of the antigen epitope corresponding to the monoclonal antibody
12. N-linked glycan of a sperm CD52 glycoform associated with human infertility
13. Reshaping human antibodies for therapy
14. Importance of antigen specificity for complement mediated lysis by monoclonal antibodies
15. The CAMPATH-1 antigen (CDw52)
16. Removal of T cells from bone marrow for transplantation: Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes
17. Structural motifs involved in human IgG antibody effector functions
18. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement
19. The GPI-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa
20. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils
21. Cell to cell transfer of glycosylphosphatidylinositol-anchored membrane proteins during sperm maturation
22. Interaction of human epididymal protein CD52 (HE5) with epididymal spermatozoa from men and cynomogus monkeys
23. GPI-anchored complement regulatory proteins in seminal plasma: An amalysis of their physical condition and the mechanisms of their binding to exogenous cells
24. Changes of the major sperm maturation-associated epididymal protein HE5 (CD52) on human ejaculated spermatozoa during incubation in capacitation conditions
25. Male-specific modification of human CD52
26. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
27. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow
28. CAMPATH-1 antibodies in stem cell transplantation
29. New Insights into the origin, structure and role of CD52: A major component of the mammalian sperm glycocalyx
30. Characterization of a cell surface glycoprotein associated with maturation of rat spermatozoa
31. Biology of the CD52 antigen, a major glycoprotein of human lymphocytes
32. Cross-linking the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes
33. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells
34. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
35. Expression of CD52 in human hematopoietic malignancies
36. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells
37. Prediction of metastatic potential in an animal model of prostate cancer: Flow cytometric quantification of cell surface charge
38. Emergence of CD52, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma
39. Emergence of CD52, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment
40. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment
41. Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation
42. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
43. CD52 antibodies for prevention of graft versus host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
44. CAMPATH-1H allows low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients
45. Humanised monclonal antibody therapy for rheumatoid arthritis
46. Humanised monoclonal antibody treatment for intractable systemic vasculitis
47. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
48. From laboratory to clinic: The story of CAMPATH-1